Navigation Links
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Date:2/19/2009

is calculated after restating full year/Q4 2008 results using full year/Q4 2007 average foreign exchange rates. Shire has delivered a strong performance in 2008: - Non GAAP diluted earnings per ADS up 36%; - New Product Sales up 110% to $1.0 bn; - New Product Sales representing 36% of total product sales, up from 22% last year; and - Strong operating cash generation and a robust balance sheet.

Angus Russell, Chief Executive Officer, commented:

"2008 saw excellent growth across the business. 2009 will see continued momentum in our business as we drive growth in existing products, pursue launches of new products and continue to develop our strong pipeline of drugs. The growth from our existing new products and our well established pipeline will be enhanced by our strategy to generate incremental returns and growth through targeted acquisitions. We will support this by continued careful management of our robust balance sheet, a focus on cash generation and flexible management of our cost base.

"We reiterate the earnings guidance framework for 2009 published in our third quarter earnings statement, and our aspiration of growing sales in the mid teens range on average between 2009 and 2015. We look forward confidently to the future."

    Full Year 2008 Unaudited Results

                                2008                        2007
                                         Non                            Non
                  US GAAP Adjustments  GAAP(1) US GAAP Adjustments    GAAP(1)

                       $M         $M       $M      $M          $M         $M
                  _______   ________ ________ _______  __________ __________
    Revenues        3,022          -    3,022   2,436           -      2,436
    Operating
    income/(loss)     412        546      958  (1,379)      2,037        658
    Net
    income/(loss)     
'/>"/>
SOURCE  Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related biology technology :

1. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
2. Shire plc: Change to Directors Details
3. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
4. Shires New Product Portfolio Delivers Strong Quarterly Performance
5. Change of Name to Shire plc
6. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
7. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
10. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
11. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...
(Date:12/15/2009)... Belgium, December 15 , ... Designed to Evaluate the Ability of,Cardiopoietic Cells to ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in ... today that it has completed, two months ahead ... pivotal Phase II/III trial of C-Cure, a,unique stem ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2
... at the 2008 Genitourinary Cancers Symposium, ... Inc. announced,today that the Company,s lead cancer ... was well-tolerated in combination with either docetaxel ... with,hormone refractory prostate cancer. Additionally, patients treated ...
... Testing the safety of chemicals ranging from pesticides to ... plan for collaboration, according to federal scientists from the ... Protection Agency (EPA), who today announced a new toxicity ... in the Feb. 15, 2008 issue of the journal ...
... summary of the National Nanotechnology Initiative (NNI) Fiscal Year ... Engineering, and Technology (NSET) Subcommittee of the National Science ... a supplement to the Presidents Budget for Fiscal Year ... as well as highlights of planned activities to be ...
Other Biology Technology:OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4NIH collaborates with EPA to improve the safety testing of chemicals 2NIH collaborates with EPA to improve the safety testing of chemicals 3National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights 2
(Date:12/14/2009)... Nations Framework Convention on Climate Change taking place ... ,Bend the Trend, event on Sunday evening to ... the screening of the new ,Environmental Atlas of ... joint project of the European Environment Agency (EEA), ... a series of short films showing the significance ...
(Date:12/13/2009)... enzymes that may help to engineer plants that take ... efficiently. The finding could help to engineer crops that ... in the carbon dioxide they need for photosynthesis through ... for each molecule of the gas gained, they lose ... pores can tighten to save water when CO 2 ...
(Date:12/13/2009)... five genetic variants that are associated with the health ... consortium of 96 scientists from 63 centres in Europe ... of lung diseases. , The new findings provide hope ... Pulmonary Disease (COPD) and asthma. In the past it ... molecular pathways that affect the health of the lung ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3New genes for lung disease discovered 2New information about how fat increases blood pressure could help identify those at risk 9752 1New information about how fat increases blood pressure could help identify those at risk 9752 2New information about how fat increases blood pressure could help identify those at risk 9752 3International event brings worlds top cancer doctors to Queens 9750 1International event brings worlds top cancer doctors to Queens 9750 2International event brings worlds top cancer doctors to Queens 9750 3Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 1Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 2Hard To Treat Diseases 28HTDS PK 29 Stem Cells and Regenerative Medicine 4931 3
... Dr Karen Beemon has been awarded the third annual Retrovirology ... crystal trophy and is interviewed in an article published today ... Chair of the Biology Department, Johns Hopkins University. , ... It is wonderful to be recognized by the ...
... energy source and use up carbon dioxide in the process, ... briefing today. , Methanogens are microbes called archaea that are ... of methane produced on earth by living things says Dr ... methane, the major flammable component of natural gas. So methanogens ...
... Raton, FL, December 8, 2007 Brain overgrowth in ... contribute to the onset of autistic characteristics, according to ... (ACNP) annual meeting. These findings support concurrent research which ... as two years old. , Lead researcher Joseph Piven, ...
Other Biology News:Karen Beemon wins the 2007 Retrovirology Prize 2New studies suggest brain overgrowth in 1-year-olds linked to development of autism 2
Purified anti-eIF-4E...
Polyclonal Antibody to CLAN...
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Biology Products: